Isolation of cultured endothelial progenitor cells in vitro from PBMCs and CD133⁺ enriched cells

Abstract

Two isolation methods for sorting of endothelial progenitor cells (EPCs): from peripheral blood mononuclear cells (PBMCs) and CD133⁺ enriched cells were compared, by defining the cell morphology, phenotype, reproductive activities and function in vitro, to provide a reference for clinical application of EPCs. PBMCs from healthy subjects were used either directly for cell culture or for CD133⁺ sorting. The two groups of cells were cultured in complete medium 199 (M199) for 7 to 14 days and the phenotypes of EPCs were analyzed by FACS. The proliferation of differentiated EPCs was studied by MTT assay, and the VEGF concentration was measured using an ELISA kit. ECM gel experiment and migration assay were performed in vivo. The results showed that PBMCs produced more colony-forming units (CFU) than CD133⁺ enriched cells from the same volume of blood (P<0.01). From day 7 to 14, the two groups showed decreased expression of hematopoietic stem cell markers and increased level of endothelial markers, but CD144⁺ cells in CD133⁺ group were less than in PBMCs group (P<0.01). PBMCs group secreted more VEGF than CD133⁺ group on the day 7 (P<0.01). As compared with CD133⁺ group, PBMCs group had more potent potential of proliferation and vascularization in vitro. It was concluded that CD133⁺ sorted cells showed a lower capacity of differentiation, secretion, proliferation and vascularization in vitro, suggesting that CD133-negative cells may be a preferential way to get EPCs for clinical therapy.

Keywords

endothelial progenitor cells / cell culture / MACS

References

[1] AsaharaT., MuroharaT., SullivanA., et al.. Isolation of putative progenitor endothelial cells for angiogenesis. Science, 1997, 275(5302): 964-967

[2] KalkaC., MasudaH., TakahashiT., et al.. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Nat Acad Sci USA, 2000, 97(7): 3422-3427

[3] Tateishi-YuyamaE., MatsubaraH., MuroharaT., et al.. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomized controlled trial. Lancet, 2002, 360(9331): 427-435

[4] SchachingerV., AssmusB., BrittenM.B., et al.. Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol, 2004, 44(8): 1690-1699

[5] BeltramiA.P., BarlucchiL., TorellaD., et al.. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell, 2003, 114(6): 763-776

[6] MienoS., ClementsR.T., BoodhwaniM., et al.. Characteristics and function of cryopreserved bone marrow-derived endothelial progenitor cells. Ann Thorac Surg, 2008, 85(4): 1361-1366

[7] HillJ.M., ZalosG., HalcoxJ.P., et al.. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med, 2003, 348(7): 593-600

[8] GulatiR., JevremovicD., PetersonT.E., et al.. Diverse origin and function of cells with endothelial phenotype obtained from adult human blood. Circ Res, 2003, 93(11): 1023-1025

[9] DomeB., TimarJ., LadanyiA., et al.. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit Rev Oncol Hematol, 2009, 69(2): 108-124

[10] GallacherL., MurdochB., WuD.M., et al.. Isolation and characterization of human CD34(−)Lin(−) and CD34(+)L in(−) hematopoietic stem cells using cell surface markers AC133 and CD7. Blood, 2000, 95(9): 2813-2820

[11] KuciS., WesselsJ.T., BühringH.J., et al.. Identification of a novel class of human adherent CD34-stem cells that give rise to SCID-repopulating cells. Blood, 2003, 101(3): 869-876

[12] GehlingU.M., ErgunS., SchumacherU., et al.. In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood, 2000, 95(10): 3106-3112

[13] LinY., WeisdorfD.J., SoloveyA., et al.. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest, 2000, 105(1): 71-77

[14] RehmanJ., LiJ., OrschellC.M., et al.. Peripheral blood ldendothelial progenitor cells” are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation, 2003, 107(8): 1164-1169

[15] EggermannJ., KlicheS., JarmyG., et al.. Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood. Cardiovasc Res, 2003, 58(2): 478-486

[16] GeorgeJ., ShmilovichH., DeutschV., et al.. Comparative analysis of methods for assessment of circulating endothelial progenitor cells. Tissue Eng, 2006, 12(2): 331-335

[17] HurJ., YangH.M., YoonC.H., et al.. Identification of a novel role of T cells in postnatal vasculogenesis: characterization of endothelial progenitor cell colonies. Circulation, 2007, 116(15): 1671-1682

[18] GordonP.R., LeimigT., MuellerI., et al.. Large-scale isolation of CD133+ progenitor cells from G-CSF mobilized peripheral blood stem cells. Bone Marrow Transplant, 2003, 31(1): 17-22

[19] YoderM.C., MeadL.E., PraterD., et al.. Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. Blood, 2007, 109(5): 1 801-1809

[20] TimmermansF., Van HauwermeirenF., De SmedtM., et al.. Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. Arterioscler Thromb Vasc Biol, 2007, 27(7): 1572-1579

[21] LuX., BaudouinS.V., GillespieJ.I., et al.. A comparison of CFU-GM, BFU-E and endothelial progenitor cells using ex vivo expansion of selected cord blood CD133(+) and CD34(+) cells. Cytotherapy, 2007, 9(3): 292-300

[22] HeT., PetersonT.E., KatusicZ.S.. Paracrine mitogenic effect of human endothelial progenitor cells: role of interleukin-8. Am J Physiol Heart Circ Physiol, 2005, 289(2): H968-972

[23] UrbichC., AicherA., HeeschenC., et al.. Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. J Mol Cell Cardiol, 2005, 39(5): 733-742

[24] NevskayaT., AnanievaL., BykovskaiaS., et al.. Autologous progenitor cell implantation as a novel therapeutic intervention for ischaemic digits in systemic sclerosis. Rheumatology (Oxford), 2009, 48(1): 61-64

[25] CañizoM.C., LozanoF., González-PorrasJ.R., et al.. Peripheral endothelial progenitor cells (CD133⁺) for therapeutic vasculogenesis in a patient with critical limb ischemia. One year follow-up. Cytotherapy, 2007, 9(1): 99-102

[26] BitanM., ShapiraM.Y., ResnickI.B., et al.. Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133⁺-purified stem cells. Exp Hematol, 2005, 33(6): 713-718